Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.76 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.97M

Average 1.17M

RCUS Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Arcus Biosciences, Inc.NYSE: RCUS

Other Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other non-current liabilities falls 22.0% from a year ago

Other non-current liabilities stood at $124M at the end of Q2 FY2026, down 22.0% from a year earlier and up 4.2% from the prior quarter. Over 3 fiscal years it compounded at +80.4% a year.

Context

  • Other non-current liabilities amounted to 13.4% of total assets at the end of Q2 FY2026, down 1.4 pp from a year earlier.
  • Other non-current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -22.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$124M+4.2% QoQ
Last fiscal yearDec 2025
$135M-14.0% YoY
Year agoJun 2025
$159M-22.0% since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.0%——
1 year-14.0%——
3-year CAGR+80.4%——
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
135M USD
Year-over-year change
-14.0%
4-year CAGR
+125.1%

Other Non-current Liabilities vs competitors

How RCUS compares with its peers on the latest reported figures

  • RCUS's Jun 2026 other non-current liabilities of $124M is the 4th highest of the 9 companies compared; the peer median is $11.22M.
  • Its year-over-year change of -22.0% is the 6th highest of 9, against a peer median of +5.7%.
  • Other non-current liabilities amounts to 13.4% of total assets for RCUS, versus a peer median of 1.8%.
RCUS Competitors Peer median
Other Non-current Liabilities for RCUS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IBRXImmunityBio, Inc.Sep 2026$794.54M +76.4%+47.5%130.4%
DNLIDenali Therapeutics Inc.Jun 2026$205.19M +1864.7%+144.4%17.7%
VRDNViridian Therapeutics, Inc.Jun 2026$129.18M +6119.7%+167.3%11.8%
RCUSArcus Biosciences, Inc.Jun 2026$124M -22.0%+80.4%13.4%
OCULOcular Therapeutix, Inc.Mar 2026$12.98M -7.3%+22.9%1.8%
LQDALiquidia CorporationJun 2026$9.46M +18.7%-10.4%1.8%
BEAMBeam Therapeutics Inc.Jun 2026$6.16M -23.4%—0.4%
COGTCogent Biosciences, Inc.Jun 2026$90K -96.2%—0.0%
AGIOAgios Pharmaceuticals, Inc.Mar 2026$90K -89.8%—0.0%
Peer median (excluding RCUS) $11.22M+5.7%+47.5%1.8%

Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents147.91M206M127M150M222M
Short-term Investments351.39M803M632M828M759M
Net Receivables746.82M43M42M25M16M
Inventory00000
Other Current Assets14.72M14M30M13M10M
Total Current Assets1.26B1.07B831M1.02B1.01B
Property, Plant & Equipment (Net)137.42M135M51M47M40M
Goodwill00000
Intangible Assets00000
Long-term Investments185M134M107M14M29M
Tax Assets00000
Other Non-current Assets7.73M10M106M73M63M
Total Non-current Assets330.15M279M264M134M132M
Total Assets1.59B1.35B1.1B1.15B1.14B
Account Payables10.26M20M17M18M42M
Short-term Debt5.1M3M000
Tax Payables1.82M001M0
Deferred Revenue102M97M91M85M35M
Other Current Liabilities30.26M48M39M14M18M
Total Current Liabilities166.08M193M184M226M231M
Long-term Debt00048M99M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)462.22M355M307M234M43M
Other Non-current Liabilities5.26M23M142M157M135M
Total Non-current Liabilities584.36M495M449M439M277M
Total Liabilities750.45M688M633M665M508M
Common Stock7K1.21B1.31B1.62B2.12B
Retained Earnings(275.35M)(542M)(849M)(1.13B)(1.49B)
Accumulated OCI(1.26M)(7M)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity841.45M657M462M485M631M
Total Debt121.99M120M11M60M112M
Net Debt(25.93M)(86M)(116M)(90M)(110M)

Arcus Biosciences, Inc.

NYSE:RCUS

Intrinsic Alpha fair value

Locked

Current Price

$15.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.